Results 61 to 70 of about 29,559 (188)

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.

PLoS ONE, 2023
BackgroundAnakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of
Jonas Sundén-Cullberg, Puran Chen, Henrike Häbel, Paul Skorup, Helena Janols, Johan Rasmuson, Katarina Niward, Åse Östholm Balkhed, Katerina Chatzidionysiou, Hilmir Asgeirsson, Ola Blennow, Åsa Parke, Anna-Karin Svensson, Jagadeeswara Rao Muvva, Hans-Gustav Ljunggren, Karolinska KI/K COVID-19 Treatment Working Group, Anna-Carin Horne, Ulrika Ådén, Jan-Inge Henter, Anders Sönnerborg, Jan Vesterbacka, Piotr Nowak, Jon Lampa   +22 more
doaj   +1 more source

Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants

Frontiers in Immunology, 2022
BackgroundBronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely.
Elys A. Green, Elys A. Green, Elys A. Green, David Metz, David Metz, David Metz, Robert Galinsky, Rebecka Atkinson, Rebecka Atkinson, Elizbeth M. Skuza, Megan Clark, Megan Clark, Alistair J Gunn, Carl M. Kirkpatrick, Rod W. Hunt, Rod W. Hunt, Rod W. Hunt, Philip J. Berger, Claudia A. Nold-Petry, Claudia A. Nold-Petry, Marcel F. Nold, Marcel F. Nold, Marcel F. Nold   +22 more
doaj   +1 more source

Chronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells [PDF]

, 2017
Skeletal complications are common features of neonatal-onset multisystem inflammatory disease (NOMID), a disorder caused by NLRP3-activating mutations. NOMID mice in which NLRP3 is activated globally exhibit several characteristics of the human disease ...
Abu-Amer, Yousef, Alippe, Yael, Civitelli, Roberto, Mbalaviele, Gabriel, Qu, Chao, Schipani, Ernestina, Wang, Chun, Xiao, Jianqiu, Xu, Can-Xin   +8 more
core   +2 more sources

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age [PDF]

, 2017
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1.
Giovanni Corsello, Luca Cantarini, Maria Cristina Maggio, Rolando Cimaz, Umberto Corpora   +4 more
core  

Development of a peptide-siRNA nanocomplex targeting NF- κB for efficient cartilage delivery [PDF]

, 2019
Delivery of therapeutic small interfering RNAs (siRNAs) in an effective dose to articular cartilage is very challenging as the cartilage dense extracellular matrix renders the chondrocytes inaccessible, even to intra-articular injections. Herein, we used
Akk, Antonina, Duan, Xin, Pan, Hua, Pham, Christine T. N., Rai, Muhammad Farooq, Sandell, Linda J., Wickline, Samuel A., Yan, Huimin   +7 more
core   +3 more sources

Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score

Epilepsia, EarlyView.
Abstract Objective This study aimed to identify risk factors and develop a predictive scoring system for autoimmune‐associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE). Methods This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of
Simona Lattanzi, Sara Matricardi, Alberto Vogrig, Giada Pauletto, Margherita Nosadini, Stefano Sartori, Federico Massa, Luana Benedetti, Stefano Meletti, Francesca Bisulli, Elena Freri, Francesca Felicia Operto, Silvia Bozzetti, Sara Mariotto, Simone Beretta, Eleonora Rosati, Elisabetta Cesaroni, Carla Marini, Tiziana Granata, Flavio Villani, Immune Epilepsies Study Group of the Italian League Against Epilepsy, Ruggero Bernabei, Stefania Maria Bova, Silva Cappanera, Luigi Caputi, Edward Cesnik, Francesco Deleo, Lidia Di Vito, Giuseppe D’Orsi, Giovanni Falcicchio, Elisa Fallica, Edoardo Ferlazzo, Lucia Fusco, Matteo Gastaldi, Giada Giovannini, Angela La Neve, Claudio Liguori, Pietro Mattioli, Lorenzo Muccioli, Carlotta Mutti, Angelo Pascarella, Elena Pasini, Daniela Passarelli, Francesca Ragona, Romana Rizzi, Elena Tartara, Valentina Tontini, Alberto Verrotti, Federica Zibordi, Lucia Zinno, Antonio Zito   +50 more
wiley   +1 more source

Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study

Scientific Reports
In our study, we aimed to evaluate the effect of high-dose intravenous anakinra treatment on the development of thrombotic events in severe and critical COVID-19 patients. This retrospective observational study was conducted at a tertiary referral center
Ramazan Çakmak, Servet Yüce, Mustafa Ay, Muhammed Hamdi Uyar, Muhammed İkbal Kılıç, Murat Bektaş   +5 more
doaj   +1 more source

A case of corticosteroid-dependent recurrent pericarditis with different response to two IL-1 blocking agents [PDF]

, 2015
Background: Recurrent pericarditis (RP) represents the most troublesome presentation of pericarditis and has a controversial pathogenesis that crosses infectious, auto-immune and auto-inflammatory pathways.
A von Scheven-Gête, F Angelini, K Theodoropoulou, M Hofer, M Prsa, S Bressieux-Degueldre, T Boulos   +6 more
core   +2 more sources

Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus

Epilepsia, EarlyView.
Abstract Objective Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods We enrolled
Aurélie Hanin, Clémence Marois, Martin Guillemaud, Mario Chavez, Léa Cosme, Zineb Hayatou, Aurore Besnard, Gwen Goudard, Véronique Masson, Louis Cousyn, Margaux Cheval, Jérôme A. Denis, Rana Alkouri, Foudil Lamari, Francesca Bisulli, Krista Eschbach, Raquel Farias‐Moeller, Nicolas Gaspard, Elizabeth E. Gerard, Giada Giovannini, Teneille Gofton, Margaret T. Gopaul, Marissa Kellogg, Stefano Meletti, Lorenzo Muccioli, Elena Pasini, Olga Taraschenko, Nathan Torcida, Mark S. Wainwright, Ji Yeoun Yoo, Nora Wong, Dominique Bonnefont‐Rousselot, Sophie Demeret, Lawrence J. Hirsch, Vincent Navarro   +34 more
wiley   +1 more source

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)

Open Access Rheumatology: Research and Reviews, 2021
Ash Bullement,1 Emma S Knowles,1 Merel Langenfeld,2 Gil Reynolds Diogo,3 Jameel Nazir,4 Daniel Eriksson4 1Delta Hat, Nottingham, UK; 2Sobi, Woluwe-Saint-Lambert, Belgium; 3Sobi, Cambridge, UK; 4Sobi, Stockholm, SwedenCorrespondence: Daniel Eriksson Email
Bullement A, Knowles ES, Langenfeld M, Diogo GR, Nazir J, Eriksson D   +5 more
doaj